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Background: Valerian is commonly used for the treatment of insomnia and anxiety. Valerian extracts allosterically
modulate GABA-A receptors and induced an anxiolytic activity. This activity is closely related to valerenic acid. In the
present experiments it was investigated whether acetoxy valerenic acid may interfere with the anxiolytic action of
valerenic acid.
Methods: Situational anxiety was measured using male CD-1 mice in the elevated plus maze test after oral
administration of the test substances. In addition the body core temperature was measured. For the 3H-GABA
binding assay dissected tissue from frontal cortex of male RjHan:WI rats were used. Statistical evaluation was
performed by means of the non-parametric Kruskal-Wallies H-test, followed by the two-tailed Mann–Whitney U-test.
Results: Adding of acetoxy valerenic acid abolished the anxiolytic action of valerenic acid. There was no effect on
body core temperature. Moreover, the valerian extract did not show any affinity to benzodiazepine binding sites.
Conclusion: The determining compound for the observed anxiolytic effect of the valerian extract is its content of
valerenic acid.
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Valerian is commonly used for the treatment of insom-
nia and anxiety. In-vitro experiments demonstrated that
valerian extracts allosterically modulate GABA-A recep-
tors [1-3], an action related to valerenic acid [4,5]. These
results were confirmed with in-vivo rodent studies [1,2].
Derivatives of valerenic acid (VA), i.e. acetoxy valere-
nic acid (AVA) or hydroxy valerenic acid (HVA), do not
allosterically modulate GABA-A receptors, but they bind
to identical binding sites [1,4]. Valerian extract (VE) was
fractionated and the fractions were tested with respect
to their ability to allosterically modulate GABA-A recep-
tors. The fractions with high VA and low AVA demon-
strated the most pronounced allosteric action [5].
Recently experiments were reported in which two VEs
were compared with respect to their anxiolytic activity
using the elevated plus maze (EPM) test. The extracts
differed in their ratio between VA and AVA. Only the ex-
tract VE-1 with the high VA and low AVA content (12:1)* Correspondence: Axel.Brattstroem@t-online.de
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unless otherwise stated.demonstrated a clear anxiolytic effect whilst VE-2 (AV:
AVA = 1:1.5) failed in this respect [6]. From these results
the suggestion comes that AVA may inhibit the anxiolytic
action of VA. To further characterise the possible VA-
AVA interaction, the active valerian extract VE-1 was
tested again in the EPM and than AVA was added in ex-
pectation that the anxiolytic activity measured in the EPM
may abolish. The applied ratio of VA to AVA corresponds
to that of commercially available VEs [7]. Again, the total
amount of VAs was kept constant.
Moreover, in vitro experiments have shown that deri-
vates of VA interact with GABA receptors. Animal stud-
ies reported that central or systemic administration of
GABA and GABA agonists produced hypothermia [8-10].
Therefore, the effect of VA-AVA combination on body
core temperature was additionally measured.
The allosteric activity of VEs and VA was reported to
occur at a binding site which is different from the benzo-
diazepine binding site [1,2]. This would explain, at least in
part, anxiolytic effects of VE. Therefore, for the extracts
used the GABA and benzodiazepine receptor binding
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Extract preparation
For the extract preparation (VE −1) valerian roots and
rhizomes from a specifically selected species were used.
A sample specimen from the selected species (HAL
115562) is preserved in the Herbarium of the Institute
of Biology, Martin Luther University Halle, Germany.
The dried starting material was mixed with hydro-
ethanol (70% V/V) in a ratio of 1:5 at 45°C for 3½ days
and then separated by filtration under 2 bar pressure.
The obtained tinctures were concentrated using a rotary
evaporator. The chromatogram of the obtained extract
is given elsewhere [6].Animals
For the behavioural experiments male CD-1 mice (Charles
River, Sulzfeld, Germany) were kept under controlled la-
boratory conditions with a light/dark cycle of 12:12 (lights
on at 06.00 a.m.), temperature 20 ± 2°C, and air humidity
between 55 and 60%. The animals had free access to com-
mercial pellets (ssniff R/M-H, ssniff Spezialdiäten GmbH,
Soest, Germany) and tap water. The animals were housed
in groups of 10 in Macrolon III cages. After arrival, the
animals were given a period of 2 weeks for habituation.
At the beginning of the experiments the mice were
8 weeks old. The number of animals per group was be-
tween 12 and 18.
For the binding experiment male RjHan:WI rats (Janvier,
Le Genest-Saint-Isle, France) were used. The rats were
kept under controlled laboratory conditions as de-
scribed above. The animals were housed in groups of
5 in Macrolon IV cages.
The work reported here was conducted in accordance
with EC regulations and the National Act on the Use of
Experimental Animals (Germany). The protocol was ap-
proved by the Saxony-Anhalt Committee on Animal
Care (42502-2-1169).Table 1 VA and AVA in different VE compositions and the











0.5 mg VA + AVA
VE - 1 12:1 1.165 0.0983 1.2633 0.400 ml
VE 1:0.5 1.165 0.583 1.748 0.286 ml
VE 1:1 1.165 1.165 2.33 0.215 ml
VE 1:1.5 1.165 1.75 2.915 0.172 mlElevated plus maze (EPM)
Situational anxiety was measured in the elevated plus
maze test [11]. The maze was made of black polyvinyl
chloride and had two open and two closed arms (50 ×
10 × 40 cm) mounted 50 cm above the floor. The floor
of the arms was smooth. Light intensity was 30 lux. A
mouse was placed on the central platform of the appar-
atus facing a closed arm. A camera on the ceiling of the
test room was used to score and tape the animals’
behaviours from an adjacent room for a period of 7 min.
The number of entries into open and closed arms, time
spent in open arms and time spent in closed arms were
measured and %time in open arms (related total time
420 s) was calculated. An entry is defined as placing
both forepaws into the given compartment of the maze.Anxiolytic drugs prolong the time spent on the open
arms. The maze was cleaned and dried after each trial.
In a first step, using the elevated plus test maze, to fur-
ther verify the hypothesis that the ratio between VA:
AVA is important for the anxiolytic activity of VE, the
aqueous extract VE-1 with the high VA and low AVA
content (12:1) was used to replicate the anxiolytic activ-
ity of 0.5 mg/ kg [6]. Then AVA (HWI Analytik GmbH,
Rülzheim, Germany) was added to the extract to change
the ratios of VA:AVA from 12:1(VE-1), to 1:0.5, 1:1, and
1:1.5, respectively. The extract amount was adapted in
such a way that the sum of VAs, i.e. VA plus AVA, was
always identical. The different extract amounts with re-
spect to their VA:AVA ratios are given in Table 1. VEs
(0.5/kg, with respect to the total sum of VA and AVA)
were administered orally (application volume 0.1 ml/
10 g body weight) using a mouse gavage feeding needle
(24 gauge, FST, Heidelberg, Germany). As control a 0.9%
saline solution was administered. A positive control has
already been reported [6]. Following the EPM, body core
temperature (BCT) was measured with a digital therm-
ometer (ama digit) manufactured by Amarell GmbH
(Kreuzwertheim, Germany).
For that purpose the lubricated probe (Ø 1 mm) was
gently inserted 3 cm into the rectum.
All behavioural tests were performed in the light period
between 8.00 a.m. and 2.00 p.m. The animals were ran-
domly assigned for testing.
Binding assay
3H-GABA (SA – 1,43 TBq/mmol) and 3H-flunitrazepam
(SA – 1,85 TBq/mmol) were obtained from PerkinElmer
(Boston, USA), diazepam and chlordiazepoxide from
AWD.pharma GmbH (Dresden, Germany). The tested
VEs were identical to those extracts VE-1 and VE-2 used
in the earlier study [6]. Assay: For the 3H-GABA bind-
ing assay tissue (dissected rat frontal cortex) was homog-
enized in 50 mM Tris–HCl buffer pH 7.4 containing
120 mM NaCl, 5 mM KCl, 2 mM CaCl2 and 1 mM
MgCl2; for
3H- flunitrazepam it was homogenized in
50 mM Tris–HCl buffer pH 7.4 containing 1 mM EGTA,
10 mM EDTA and 3 mM MgCl2, centrifuged (50.000 g,
15 min) and washed twice with the corresponding buffer.
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of the crude membrane suspension (50 μg protein) were
incubated for 45 min at 37°C with 2.5 nM 3H-GABA or 1
nM 3H-flunitrazepam at 0–4°C for 60 min. Specific bind-
ing was calculated by subtracting non-specific binding –
defined as that seen in the presence of 1 μM unlabelled
GABA or 1 μM diazepam or chlordiazepoxide – from the
total binding obtained with radioligand alone. In parallel
VE-1, VE-2 and AVA were used for all binding assays. The
incubation was terminated by addition of ice-cold buffer
and rapid filtration through glass fibre filters. The filters
were washed, dried, a scintillation cocktail was added, and
radioactivity was counted using a β-counter (Beckman
Coulter, Germany). The EC50 values were determined by
the addition of unlabelled drugs (GABA, chlordiazepoxide,
diazepam, AVA, VE-1 and VE-2) over a wide concentra-
tion range (10−10 to 10−4 M).
Statistics
Due to non-Gaussian distribution of the data obtained
in the elevated plus maze, for statistical evaluation the
non-parametric Kruskal-Wallies H-test, followed by the
two-tailed Mann–Whitney U-test were used. Body core
temperature was analyzed using ANOVA. The threshold
for significance was set at p < 0.05.
Results
Elevated plus maze
For the animal groups treated with 0.5 mg VAs /kg with
added AVA a significant effect was found (Χ2 4, 87 = 24.37,
p < 0.001). The control animals (treated with saline) spent
15.15 ± 1.76% time in the open arm. Animals which hadFigure 1 % Time spent in the open arm, total arm changes, number o
body core temperature (mean ± sem) for the different 0.5 mg/kg vale
of added AVA to VE is indicated (mg AVA), n equals the number of animalreceived VE (total amount of VAs 0.5 mg/kg; VA:AVA =
12:1) exhibited extended times in the open arm (20.16 ±
1.24%; U 2, 18, 17 = 89.0, p = 0.035). This is a significant
anxiolytic effect (Figure 1). The results of the other animal
groups, which had received VE with different ratios of
VAs (VA : AVA = 1:0.5 or 1:1.5) were either in the range of
the saline control group or demonstrated just the opposite
effect, i.e. an anxiogenic action (VA:AVA = 1:1; U 2, 18, 18 =
79.5, p = 0.008).
The number of total arm changes (Χ2 4, 87 = 4.89, p =
0.298, Figure 1) and entries in open arms (Χ2 4, 87 = 7.39,
p = 0.12, Figure 1) were similar in all experimental groups.Body core temperature
The BCT remained for all experimental groups in the
control range (0.5 mg/kg, F 4, 82 = 0.725, p = 0.725). In
one animal BCT was reduced to be below 34°C (0.5 mg/
kg = 1). The result of this animal was disregarded for
data evaluation.Binding assay
Both of the tested valerian extracts did not bind at 3H-
flunitrazepam labelled binding sites of the benzodiazep-
ine receptors, while diazepam (EC50: 0.40 ± 0.05 μM)
as well as chlordiazepoxide did (EC50: 0.64 ± 0.08 μM).
At the crude synaptosomal membranes GABA (EC50:
1.82 ± 0.21 μM) as well as VE-1 (EC50: 5.61 ± 1.68 μM)
and VE-2 (EC50: 10.04 ± 1.34 μM) compete with 3H-
GABA at the GABA binding site, whilst AVA did not.
The binding affinity was more expressed with VE-1
compared to VE-2.f entries in open arms (median ± deviation of the median) and
rian extract – acetoxy valerianic combinations (AVA). The amount
s used. *p < 0.05 in comparison to saline.
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Oral administration of a valerian extract (VA: 0.5 mg/kg)
with high VA and very low AVA content (12:1) produced
a significant anxiolytic activity. As shown in Figure 1 the
experimental groups did not significantly differ in the
two parameters reflecting locomotor activity, i.e. entries
in open arms and total arm changes. This indicates that
the anxiolytic effect is not affected by locomotor activity.
This result is in accordance with a recent report in
which diazepam (1 mg) was included as positive control
[6]. Adding AVA to this valerian extract abolished the
anxiolytic action, which underlines the competition of
both acids at the binding sites [1,4]. The ratios of VA
and AVA in the range of 1:0.5, 1:1 and 1:1.5 are the most
frequent ratios reported for standard preparations of val-
erian root [7], whereas hydroxy-valerenic acid as an
AVA metabolite is not important in this context [12].
Interestingly, the dose–response curve for the anxiolytic
effect of the different VA: AVA combinations are not lin-
ear. An elevated concentration of AVA was reported to
close the open GABA-A channel and thus limits its
action [4]. This might explain the dose–response curve
in regard to the parameter %time spent in open arms as
shown in Figure 1. However, the behavioural effect of in-
creasing AVA concentrations has to be considered in re-
lation to the concentration of its VA competitor.
Whether or not the anxiolytic action of VE is restricted
to its VA acid content is an open question, since valerenol,
6-methylapigenin and linarin, i.e. other components of the
extract, also demonstrate activity at the GABA channel
[1,13,14]. These results however were obtained from in-
vitro experiments and confirmation from in-vivo studies is
still lacking.
Moreover, VE was more active than the detected
amount of VA [1,15], a fact which may point to the par-
ticipation of other components or indicates that other
components of the extract influence VA bioavailability,
since bioavailability of VA after oral administration was
33.7% [16].
From other in-vitro experiments a VE mediated inhib-
ition of cerebral GABA degradation enzymes was reported,
whereby the VE activity may have been additionally en-
hanced [17]. Moreover, VE and VA also interact with glu-
tamate receptors, from which an anxiolytic effect can also
be induced [18]. For both of the latter reports confirmation
from in-vivo conditions is not as yet available.
Although the combination with different amounts of
AVA did reduce the anxiolytic effect of VE-1 (Figure 1),
we did find no effect of VE-1 or the combinations with
AVA on BCT. It was found that intraperitoneal injection
of diazepam (1.5 - 6 mg/kg) decreased the BCT of the
rats [9]. This implies that the hypothermic effect is bas-
ing on doses of this substance which are supramaximal
in relation to its anxiolytic effects. Considering the dose-effect relation concerning the anxiolytic effect found re-
ported in a recent study [6] this might explain that lack
of alterations in BCT underlining the therapeutical use-
fulness of valerian extract.
Short-acting benzodiazepines are the first line option
for the treatment of anxiety disorders. Besides their limi-
tations regarding treatment duration and adverse events,
a correlation to being a risk factor for dementia was re-
ported quite recently [19]. Benzodiazepines bind to the
α + γ- subunits at the GABA-A channel [20]. The tested
valerian extracts (VE-1, VE-2) failed in this respect.
However, there are other subunits for binding [21] and
other ways of GABA receptor modulation. It may be
worthwhile to mention in this context that VA binds to
the β + α- subunit [1,4], i.e. its action occurs not at the
benzodiazepine binding site and may therefore basically
provide clinically relevant advantages particularly regard-
ing impairments in the domain of cognition. The inter-
action between VA and AVA in the EPM can not be
explained based on the binding data presented here. For
this reason more elaborate tests directly at the β + α-
subunits are necessary.
Conclusion
In conclusion, the VA content of VE seems to be an im-
portant factor for the observed anxiolytic activity. AVA
may modulate this action. Hitherto based on the mono-
graph for valerian the sum of VA and AVA contents is
expressed as VA (Ph Eur. monograph 0453). Considering
the presented results, this declaration is misleading. VA
and AVA should be separately declared to provide a
basis for the expected anxiolytic activity of that VE. The
observed anxiolytic VE activity is not mediated via the
benzodiazepine binding site. VA as a natural compound
may belong to a new class of substances with the cap-
ability to allosterically modulate the GABA-A channel.
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